Stem definition | Drug id | CAS RN |
---|---|---|
779 | 17230-88-5 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 33.78 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 5.18 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 15.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.31 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 21, 1976 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 137.11 | 21.44 | 33 | 1765 | 5409 | 50597917 |
Platelet count decreased | 58.08 | 21.44 | 39 | 1759 | 100687 | 50502639 |
Hypoperfusion | 33.12 | 21.44 | 8 | 1790 | 1322 | 50602004 |
Bone marrow reticulin fibrosis | 29.40 | 21.44 | 5 | 1793 | 140 | 50603186 |
Myelofibrosis | 24.00 | 21.44 | 6 | 1792 | 1141 | 50602185 |
Therapeutic response decreased | 21.81 | 21.44 | 16 | 1782 | 47215 | 50556111 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coombs positive haemolytic anaemia | 180.93 | 25.38 | 33 | 1972 | 719 | 29571803 |
Lymphadenitis | 155.92 | 25.38 | 33 | 1972 | 1574 | 29570948 |
Haemolysis | 134.04 | 25.38 | 39 | 1966 | 6917 | 29565605 |
Hereditary angioedema | 105.35 | 25.38 | 21 | 1984 | 740 | 29571782 |
Migraine | 89.14 | 25.38 | 33 | 1972 | 12397 | 29560125 |
Myelofibrosis | 70.63 | 25.38 | 17 | 1988 | 1445 | 29571077 |
Hepatic enzyme increased | 68.52 | 25.38 | 37 | 1968 | 33762 | 29538760 |
Infusion related reaction | 67.26 | 25.38 | 40 | 1965 | 43846 | 29528676 |
Therapeutic product effect decreased | 56.23 | 25.38 | 31 | 1974 | 29420 | 29543102 |
Myelodysplastic syndrome | 49.11 | 25.38 | 24 | 1981 | 17770 | 29554752 |
Rhabdomyolysis | 44.22 | 25.38 | 35 | 1970 | 60773 | 29511749 |
Drug ineffective | 37.29 | 25.38 | 78 | 1927 | 363092 | 29209430 |
Constipation | 37.07 | 25.38 | 42 | 1963 | 114118 | 29458404 |
Bone marrow reticulin fibrosis | 31.55 | 25.38 | 6 | 1999 | 164 | 29572358 |
Therapeutic response decreased | 31.35 | 25.38 | 20 | 1985 | 24691 | 29547831 |
Platelet count decreased | 29.77 | 25.38 | 36 | 1969 | 104636 | 29467886 |
Cushingoid | 27.16 | 25.38 | 9 | 1996 | 2429 | 29570093 |
Neutropenia | 26.18 | 25.38 | 38 | 1967 | 131673 | 29440849 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coombs positive haemolytic anaemia | 184.62 | 21.56 | 33 | 3304 | 845 | 64494550 |
Hereditary angioedema | 156.46 | 21.56 | 37 | 3300 | 3839 | 64491556 |
Lymphadenitis | 136.55 | 21.56 | 33 | 3304 | 3752 | 64491643 |
Haemolysis | 113.93 | 21.56 | 36 | 3301 | 11003 | 64484392 |
Rhabdomyolysis | 68.10 | 21.56 | 48 | 3289 | 91678 | 64403717 |
Myelofibrosis | 63.33 | 21.56 | 16 | 3321 | 2177 | 64493218 |
Platelet count decreased | 63.16 | 21.56 | 59 | 3278 | 167652 | 64327743 |
Migraine | 56.49 | 21.56 | 37 | 3300 | 62640 | 64432755 |
Bone marrow reticulin fibrosis | 48.91 | 21.56 | 9 | 3328 | 271 | 64495124 |
Myelodysplastic syndrome | 45.25 | 21.56 | 24 | 3313 | 27555 | 64467840 |
Hepatic enzyme increased | 41.86 | 21.56 | 42 | 3295 | 129901 | 64365494 |
Immune thrombocytopenia | 36.22 | 21.56 | 17 | 3320 | 15049 | 64480346 |
Infusion related reaction | 32.14 | 21.56 | 41 | 3296 | 164426 | 64330969 |
Cushingoid | 29.43 | 21.56 | 12 | 3325 | 7591 | 64487804 |
Therapeutic product effect decreased | 27.81 | 21.56 | 32 | 3305 | 115319 | 64380076 |
Mucosal haemorrhage | 25.86 | 21.56 | 8 | 3329 | 2273 | 64493122 |
Hypoperfusion | 25.64 | 21.56 | 8 | 3329 | 2338 | 64493057 |
Gingival bleeding | 24.56 | 21.56 | 13 | 3324 | 14841 | 64480554 |
Constipation | 24.38 | 21.56 | 43 | 3294 | 229294 | 64266101 |
Therapeutic response decreased | 22.79 | 21.56 | 20 | 3317 | 52168 | 64443227 |
Non-cirrhotic portal hypertension | 22.52 | 21.56 | 5 | 3332 | 390 | 64495005 |
Splenomegaly | 22.25 | 21.56 | 13 | 3324 | 17948 | 64477447 |
Drug ineffective | 21.57 | 21.56 | 93 | 3244 | 840154 | 63655241 |
None
Source | Code | Description |
---|---|---|
ATC | G03XA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Antigonadotropins and similar agents |
FDA CS | M0001109 | Androstanes |
FDA MoA | N0000000146 | Androgen Receptor Agonists |
CHEBI has role | CHEBI:50751 | anti-estrogenic drug |
CHEBI has role | CHEBI:50837 | oestrogen antagonist |
CHEBI has role | CHEBI:176497 | geroprotectors |
MeSH PA | D004965 | Estrogen Antagonists |
MeSH PA | D006727 | Hormone Antagonists |
FDA EPC | N0000175824 | Androgen |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Fibrocystic breast changes | indication | 27431007 | DOID:10354 |
Endometriosis | indication | 129103003 | |
Hereditary Angioedema Prevention | indication | ||
Gynecomastia | off-label use | 4754008 | DOID:12698 |
Menorrhagia | off-label use | 386692008 | |
Precocious puberty | off-label use | 400179000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Chronic heart failure | contraindication | 48447003 | |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Mixed hyperlipidemia | contraindication | 267434003 | |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Porphyria | contraindication | 418470004 | |
Carcinoma of female breast | contraindication | 447782002 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Androgen receptor | Nuclear hormone receptor | AGONIST | UNKNOWN | CHEMBL | |||||
Progesterone receptor | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.09 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.25 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.60 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 4.98 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.01 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.43 | DRUG MATRIX | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.71 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 4.89 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 5.46 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.27 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.20 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.21 | DRUG MATRIX | |||||
Estrogen receptor | Nuclear hormone receptor | Ki | 5.29 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
Steryl-sulfatase | Enzyme | WOMBAT-PK | |||||||
Sex hormone-binding globulin | Secreted | Kd | 8.20 | CHEMBL | |||||
Substance-K receptor | GPCR | Ki | 5.05 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 4.99 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | Ki | 8.10 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 7.47 | DRUG MATRIX |
ID | Source |
---|---|
4018233 | VUID |
N0000146564 | NUI |
D00289 | KEGG_DRUG |
258343 | RXNORM |
4018233 | VANDF |
C0010961 | UMLSCUI |
CHEBI:4315 | CHEBI |
QA1 | PDB_CHEM_ID |
CHEMBL1479 | ChEMBL_ID |
DB01406 | DRUGBANK_ID |
D003613 | MESH_DESCRIPTOR_UI |
28417 | PUBCHEM_CID |
6942 | IUPHAR_LIGAND_ID |
2556 | INN_ID |
N29QWW3BUO | UNII |
3093 | MMSL |
4533 | MMSL |
605 | MMSL |
d00204 | MMSL |
002116 | NDDF |
126124009 | SNOMEDCT_US |
87881000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1368 | CAPSULE | 100 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1369 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1392 | CAPSULE | 50 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0633 | CAPSULE | 50 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0634 | CAPSULE | 100 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0635 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-243 | CAPSULE | 200 mg | ORAL | ANDA | 16 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2298 | CAPSULE | 200 mg | ORAL | ANDA | 21 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-861 | CAPSULE | 100 mg | ORAL | ANDA | 17 sections |
Danazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-862 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |